ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 285

Rituximab for Severe Disease Flares in Childhood ANCA Vasculitides

Marinka Twilt1, Rayfel Schneider2, Audrey Bell-Peter1, Sharon Dell3 and Susanne M. Benseler4, 1Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 2Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Canada, 3Respiratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada, 4Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: ANCA and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Children with ANCA vasculitides frequently present with life-threatening organ manifestations including alveolar hemorrhage, critical subglottic stenosis and renal failure due to rapidly progressive glomerulonephritis (GN). The current initial management for adults includes high-dose steroids and cyclophosphamide. The majority of patients experience a serious disease flare. In adult studies, Rituximab is highly effective in the treatment of severe vasculitis flares. The aim of this study was to evaluate efficacy and safety of Rituximab for treatment of severe disease flare in children with ANCA vasculitides.

Methods: A single-center cohort study of consecutive children with ANCA vasculitis treated with Rituximab for severe disease flares was performed between January 2009 until July 2011. Children were managed according to a previously implemented protocol. Clinical, laboratory and imaging features, previous therapies, including efficacy and safety were documented in serial assessments. Disease activity was captured by Pediatric Vasculitis Activity Score (PVAS). Safety evaluation included adverse events and disease-related damage domains by Vasculitis Damage index (VDI).

Results:

Six children (5 females, 1 male) were included, median age at diagnosis 7.8 years. Diagnosis: All children had lung involvement including 4 presenting with hemorrhage, 3 with renal disease and 3 with ENT involvement, including subglottic stenosis in 2. ANCAs: +c-ANCA +PR3 in 4 patients, + p-ANCA +MPO in 1 and -ANCA + MPO in 1. All children previously received high dose steroids and cyclophosphamide; previous maintenance treatment included: azathioprine in 1, MMF in 2 and MTX in 4 children. Two patients were still on MTX maintenance at time of flare. Disease flare: median disease duration until time to flare was 16 months (12-62 months); 5/6 had lung flares (hemorrhage, new nodules) and 1 child developed new GN. Treatment: All 6 children received Rituximab (500 mg/m2, 2 doses q2weeks) plus high dose prednisone (2 mg/kg/day, max 60 mg/day) and one patients continued on MTX maintenance. Plasmapheresis just prior to Rituximab was used in 2 children. Efficacy: The median PVAS at time of flare was 6; 4 children had no evidence of active disease at 3 months (PVAS=0), and 5 at 12 months. All patients completely depleted their B-cells. After Rituximab therapy, ANCAs were positive in 4 patients at 3 months and 2 patients after 12 months. Safety: Infusion reactions were uncommon. One child experienced itchiness, fever and myalgias during the 2nd cycle of infusions. One patient developed Pneumocystis Jiroveci pneumonia. Five children received a second course of Rituximab at 6-13 months postinitial course upon return of their B-cells.

Conclusion:

A complete response (PVAS=0) was seen in 67% of children with severe disease flares of ANCA vasculitis following treatment with Rituximab and high dose prednisone. This is a significantly higher response rate than with the current induction treatment for childhood ANCA vasculitides. Retreatment with Rituximab was required in the majority of children. Rituximab therapy was effective and safe; however long-term observations will determine the safety of repeated Rituximab treatment.


Disclosure:

M. Twilt,
None;

R. Schneider,

Hoffmann-La Roche, Inc.,

5,

Hoffmann-La Roche, Inc.,

8,

Innomar Strategies,

5;

A. Bell-Peter,
None;

S. Dell,
None;

S. M. Benseler,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rituximab-for-severe-disease-flares-in-childhood-anca-vasculitides/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology